We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Is Arbutus Biopharma (ABUS) Stock Outpacing Its Medical Peers This Year?
Read MoreHide Full Article
For those looking to find strong Medical stocks, it is prudent to search for companies in the group that are outperforming their peers. Arbutus Biopharma (ABUS - Free Report) is a stock that can certainly grab the attention of many investors, but do its recent returns compare favorably to the sector as a whole? By taking a look at the stock's year-to-date performance in comparison to its Medical peers, we might be able to answer that question.
Arbutus Biopharma is one of 973 individual stocks in the Medical sector. Collectively, these companies sit at #8 in the Zacks Sector Rank. The Zacks Sector Rank considers 16 different groups, measuring the average Zacks Rank of the individual stocks within the sector to gauge the strength of each group.
The Zacks Rank is a proven model that highlights a variety of stocks with the right characteristics to outperform the market over the next one to three months. The system emphasizes earnings estimate revisions and favors companies with improving earnings outlooks. Arbutus Biopharma is currently sporting a Zacks Rank of #2 (Buy).
Over the past 90 days, the Zacks Consensus Estimate for ABUS' full-year earnings has moved 15.6% higher. This signals that analyst sentiment is improving and the stock's earnings outlook is more positive.
Based on the latest available data, ABUS has gained about 13.5% so far this year. Meanwhile, the Medical sector has returned an average of -2.3% on a year-to-date basis. This means that Arbutus Biopharma is performing better than its sector in terms of year-to-date returns.
One other Medical stock that has outperformed the sector so far this year is Armata Pharmaceuticals, Inc. (ARMP - Free Report) . The stock is up 35.1% year-to-date.
The consensus estimate for Armata Pharmaceuticals, Inc.'s current year EPS has increased 24.7% over the past three months. The stock currently has a Zacks Rank #2 (Buy).
Breaking things down more, Arbutus Biopharma is a member of the Medical - Biomedical and Genetics industry, which includes 486 individual companies and currently sits at #103 in the Zacks Industry Rank. Stocks in this group have gained about 2.7% so far this year, so ABUS is performing better this group in terms of year-to-date returns. Armata Pharmaceuticals, Inc. is also part of the same industry.
Investors with an interest in Medical stocks should continue to track Arbutus Biopharma and Armata Pharmaceuticals, Inc.. These stocks will be looking to continue their solid performance.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Is Arbutus Biopharma (ABUS) Stock Outpacing Its Medical Peers This Year?
For those looking to find strong Medical stocks, it is prudent to search for companies in the group that are outperforming their peers. Arbutus Biopharma (ABUS - Free Report) is a stock that can certainly grab the attention of many investors, but do its recent returns compare favorably to the sector as a whole? By taking a look at the stock's year-to-date performance in comparison to its Medical peers, we might be able to answer that question.
Arbutus Biopharma is one of 973 individual stocks in the Medical sector. Collectively, these companies sit at #8 in the Zacks Sector Rank. The Zacks Sector Rank considers 16 different groups, measuring the average Zacks Rank of the individual stocks within the sector to gauge the strength of each group.
The Zacks Rank is a proven model that highlights a variety of stocks with the right characteristics to outperform the market over the next one to three months. The system emphasizes earnings estimate revisions and favors companies with improving earnings outlooks. Arbutus Biopharma is currently sporting a Zacks Rank of #2 (Buy).
Over the past 90 days, the Zacks Consensus Estimate for ABUS' full-year earnings has moved 15.6% higher. This signals that analyst sentiment is improving and the stock's earnings outlook is more positive.
Based on the latest available data, ABUS has gained about 13.5% so far this year. Meanwhile, the Medical sector has returned an average of -2.3% on a year-to-date basis. This means that Arbutus Biopharma is performing better than its sector in terms of year-to-date returns.
One other Medical stock that has outperformed the sector so far this year is Armata Pharmaceuticals, Inc. (ARMP - Free Report) . The stock is up 35.1% year-to-date.
The consensus estimate for Armata Pharmaceuticals, Inc.'s current year EPS has increased 24.7% over the past three months. The stock currently has a Zacks Rank #2 (Buy).
Breaking things down more, Arbutus Biopharma is a member of the Medical - Biomedical and Genetics industry, which includes 486 individual companies and currently sits at #103 in the Zacks Industry Rank. Stocks in this group have gained about 2.7% so far this year, so ABUS is performing better this group in terms of year-to-date returns. Armata Pharmaceuticals, Inc. is also part of the same industry.
Investors with an interest in Medical stocks should continue to track Arbutus Biopharma and Armata Pharmaceuticals, Inc.. These stocks will be looking to continue their solid performance.